UroGen Pharma (URGN) Assets (2016 - 2026)
UroGen Pharma's (URGN) quarterly Assets came in at $253.7 million in Q1 2026, up 2.45% YoY from $247.6 million in Q1 2025, and up 26.56% on a QoQ basis from $200.5 million in Q4 2025.
UroGen Pharma (URGN) Assets (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Assets data on file, last reported at $253.7 million in Q1 2026.
- Quarterly Assets rose 2.45% year-over-year to $253.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $253.7 million (up 2.45% YoY) and the FY2025 annual result came in at $200.5 million, down 29.84% from the prior year.
- Assets climbed to $253.7 million in Q1 2026, from $200.5 million in the prior quarter.
- In the past five years, Assets ranged from a high of $301.9 million in Q3 2024 to a low of $95.4 million in Q2 2023.
- A 5-year average of $195.4 million and a median of $193.6 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets surged 195.56% — and 2025, when it tumbled 38.71%.
- Tracing URGN's Assets over 5 years: stood at $135.6 million in 2022, then soared by 31.48% to $178.3 million in 2023, then surged by 60.23% to $285.7 million in 2024, then fell by 29.84% to $200.5 million in 2025, then climbed by 26.56% to $253.7 million in 2026.
- The last three Assets figures came in at $253.7 million (Q1 2026), $200.5 million (Q4 2025), and $185.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 252.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 252.59 Mn |
| Mar 31, 2026 | 253.69 Mn |
| Dec 31, 2025 | 200.46 Mn |
| Sep 30, 2025 | 185.05 Mn |
| Jun 30, 2025 | 208.72 Mn |
| Mar 31, 2025 | 247.62 Mn |
| Dec 31, 2024 | 285.71 Mn |
| Sep 30, 2024 | 301.94 Mn |
| Jun 30, 2024 | 281.85 Mn |
| Mar 31, 2024 | 200.57 Mn |
| Dec 31, 2023 | 178.31 Mn |
| Sep 30, 2023 | 193.63 Mn |
| Jun 30, 2023 | 95.36 Mn |
| Mar 31, 2023 | 112.95 Mn |
| Dec 31, 2022 | 135.62 Mn |
| Sep 30, 2022 | 128.47 Mn |
| Jun 30, 2022 | 146.14 Mn |
| Mar 31, 2022 | 165.72 Mn |
| Dec 31, 2021 | 119.75 Mn |
| Sep 30, 2021 | 134.60 Mn |